分子プロファイリング

Evaluating Relapse Risks and the Role of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma

By MedXY 09/14/2026

This analysis of localized appendiceal adenocarcinoma reveals low relapse rates post-resection, identifies key histopathologic and molecular relapse predictors, and finds no significant benefit from adjuvant chemotherapy, challenging conventional colorectal cancer treatment paradigms.

Hematology-Oncology news Oncology

Molecular Profiling Refines Relapse Risk After Allogeneic Transplant in First-Remission Acute Myeloid Leukemia

By MedXY 05/11/2026

A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.

news Oncology Pathology & Lab Medicine

Selective vs. Universal NGS in Endometrial Cancer: A Cost-Efficiency Breakthrough

By MedXY 04/23/2026

A new study reveals that selective molecular profiling with MMR/p53 IHC followed by NGS for p53-abnormal tumors is more cost-efficient than universal NGS for advanced endometrial cancer, reducing unnecessary testing by 57%.

news Oncology Respiratory

Precision Management of KRAS G12V-Mutated NSCLC: Molecular Insights and Therapeutic Strategies

By MedXY 01/11/2026

This article synthesizes recent findings on the KRAS G12V mutation in non-small cell lung cancer, highlighting its unique molecular profile, strong association with smoking, and superior response to immunotherapy compared to traditional chemotherapy.